CN111184805B - Traditional Chinese medicine composition and application thereof - Google Patents

Traditional Chinese medicine composition and application thereof Download PDF

Info

Publication number
CN111184805B
CN111184805B CN202010151714.8A CN202010151714A CN111184805B CN 111184805 B CN111184805 B CN 111184805B CN 202010151714 A CN202010151714 A CN 202010151714A CN 111184805 B CN111184805 B CN 111184805B
Authority
CN
China
Prior art keywords
parts
weight
traditional chinese
chinese medicine
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010151714.8A
Other languages
Chinese (zh)
Other versions
CN111184805A (en
Inventor
雷鸣
养立
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangxi Caodong Charity Foundation
Original Assignee
Jiangxi Caodong Charity Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangxi Caodong Charity Foundation filed Critical Jiangxi Caodong Charity Foundation
Priority to CN202010151714.8A priority Critical patent/CN111184805B/en
Publication of CN111184805A publication Critical patent/CN111184805A/en
Application granted granted Critical
Publication of CN111184805B publication Critical patent/CN111184805B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/076—Poria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/233—Bupleurum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/34—Campanulaceae (Bellflower family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/34—Campanulaceae (Bellflower family)
    • A61K36/342—Adenophora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/34—Campanulaceae (Bellflower family)
    • A61K36/344—Codonopsis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/34—Campanulaceae (Bellflower family)
    • A61K36/346—Platycodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A61K36/428—Trichosanthes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539—Scutellaria (skullcap)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A61K36/634—Forsythia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A61K36/808—Scrophularia (figwort)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A61K36/8888—Pinellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/894—Dioscoreaceae (Yam family)
    • A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Insects & Arthropods (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention provides a traditional Chinese medicine composition which comprises tripterygium wilfordii, gypsum, raw Chinese yam, figwort root, forsythia, cicada slough, codonopsis pilosula and the like. The traditional Chinese medicine composition disclosed by the invention takes tripterygium wilfordii as a main formula, has a good effect on resisting viruses and regulating immunity, and particularly has a good curative effect when being applied to treating 2019 novel coronavirus pneumonia and other pulmonary infections.

Description

Traditional Chinese medicine composition and application thereof
Technical Field
The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition and application thereof.
Background
Viral infection refers to the process by which a virus invades the body and proliferates in cells of a target organ, interacting with the body. After the acute virus infection enters the body, the virus proliferates in cells and suddenly attacks after a latency period of several days or even several weeks. During the latent period, the virus proliferates to a certain level, causing damage to target cells and even cell death, thereby causing damage and dysfunction of tissues and organs, and presenting clinical symptoms. The host mobilizes non-specific and specific immune factors to clear the virus. Its advantages are short latent period, quick onset and several days to several weeks.
The pestilence diseases and disasters caused by viruses are very close to human beings, such as smallpox, poliomyelitis (poliomyelitis), Severe Acute Respiratory Syndrome (SARS), Ebola virus disease and Middle East Respiratory Syndrome (MERS) are near to the epidemic plague diseases and disasters, and about 29.1 to 64.6 million people die due to respiratory diseases related to influenza viruses worldwide each year.
From SARS to 2019, viral pneumonia threatens human health all the time, viral infection belongs to intracellular infection, and cannot be treated by antibiotic drugs, and the virus is usually eliminated by generating antibodies by the autoimmune response of patients. The severity of the disease is closely related to the level of autoimmunity of the patient. The disease condition is relatively mild, and the virus is eliminated by resting and improving the autoimmune capacity. Severe patients are also severely complicated by complications such as respiratory failure and even multiple organ failure, requiring Intensive Care Unit (ICU) recovery for rescue.
The virus has the characteristics of multiple types and quick variation, long links such as virus sequencing, virus vector recombination, positive clone screening, animal experiments, clinical tests and the like are required for developing vaccines aiming at novel viruses, and the specificity of the vaccine is reduced along with the variation of the virus. In clinical treatment, the traditional Chinese medicine for treating the infectious diseases caused by virus infection is found to generate more excellent treatment effect.
Tripterygium wilfordii belongs to a Chinese herbal medicine, is bitter in nature, enters heart and liver channels, has the effects of dispelling wind and removing dampness, promoting blood circulation and removing obstruction in channels, relieving swelling and pain, and killing parasites and detoxifying, and has a good curative effect on viral infection.
The novel coronavirus pneumonia in 2019 has rapid outbreak and strong infectivity, so that a Chinese medicament aiming at the novel coronavirus pneumonia and other pulmonary infections in 2019 is urgently needed to be found as soon as possible, and the Chinese medicament has a good curative effect on infected patients, particularly severe patients.
Disclosure of Invention
In order to overcome the problems in the prior art, the invention provides a traditional Chinese medicine composition and application thereof in antivirus and immunity regulation, and particularly has a good treatment effect on 2019 novel coronavirus pneumonia.
The invention provides the following technical scheme:
a traditional Chinese medicine composition, the composition comprising: 3-15 parts of tripterygium wilfordii, 10-50 parts of gypsum, 8-24 parts of raw Chinese yam, 5-15 parts of radix scrophulariae, 4-12 parts of fructus forsythiae, 4-10 parts of periostracum cicada, 4-12 parts of codonopsis pilosula, 3-8 parts of mint, 3-10 parts of burdock and 4-20 parts of raw ochre.
Further, 7.5 parts by weight of tripterygium wilfordii, 15 parts by weight of gypsum, 8 parts by weight of raw Chinese yam, 5 parts by weight of radix scrophulariae, 4 parts by weight of fructus forsythiae, 4 parts by weight of periostracum cicada, 4 parts by weight of radix codonopsis, 3 parts by weight of mint, 3 parts by weight of burdock and 4 parts by weight of raw ochre.
A traditional Chinese medicine composition, the composition comprising: 2-5 parts of tripterygium wilfordii, 5-10 parts of radix bupleuri, 5-10 parts of pinellia ternate, 3-8 parts of scutellaria baicalensis, 10-20 parts of reed stems, 5-10 parts of exocarpium citri rubrum, 5-10 parts of adenophora stricta, 5-10 parts of radix peucedani, 3-8 parts of platycodon grandiflorum, 5-10 parts of almonds and 3-8 parts of honey-fried licorice roots.
Further, 3 parts by weight of tripterygium wilfordii, 9 parts by weight of radix bupleuri, 9 parts by weight of pinellia ternate, 6 parts by weight of radix scutellariae, 15 parts by weight of reed stem, 9 parts by weight of exocarpium citri rubrum, 9 parts by weight of adenophora stricta, 9 parts by weight of radix peucedani, 6 parts by weight of platycodon grandiflorum, 9 parts by weight of almond and 6 parts by weight of honey-fried licorice root.
A traditional Chinese medicine composition, the composition comprising: 2-5 parts of tripterygium wilfordii, 10-15 parts of snakegourd fruit, 5-10 parts of allium macrostemon, 3-8 parts of poria cocos, 5-10 parts of rhizoma pinellinae praeparata, 3-8 parts of dried orange peel, 3-8 parts of immature bitter orange, 5-10 parts of bamboo shavings, 3-8 parts of rhizoma acori graminei and 3-8 parts of honey-fried licorice root.
Further, 3 parts of tripterygium wilfordii, 12 parts of snakegourd fruit, 9 parts of allium macrostemon, 6 parts of poria cocos, 9 parts of rhizoma pinellinae praeparata, 6 parts of dried orange peel, 6 parts of immature bitter orange, 9 parts of bamboo shavings, 6 parts of rhizoma acori graminei and 6 parts of honey-fried licorice root.
Furthermore, the traditional Chinese medicine composition has the functions of resisting viruses and regulating the immunity of the organism.
Furthermore, the traditional Chinese medicine composition has the functions of defervescence and virus elimination aiming at the novel coronavirus pneumonia diseases.
Furthermore, the traditional Chinese medicine composition has the functions of relieving cough and asthma aiming at the novel coronavirus pneumonia diseases.
Furthermore, the traditional Chinese medicine composition has the functions of removing blood stasis, activating yang, harmonizing stomach, benefiting gallbladder and recovering digestive function aiming at the novel coronavirus pneumonia disease. .
By adopting the technical scheme, the invention has the following beneficial effects:
1. the traditional Chinese medicine composition disclosed by the invention is simple in traditional Chinese medicine components, has a good effect on resisting viruses and regulating immunity, and has a good curative effect when being applied to treating 2019 novel coronavirus pneumonia and other pulmonary infections.
2. The traditional Chinese medicine composition disclosed by the invention takes tripterygium wilfordii as a main formula, and distinguishes the symptoms of three stages of the disease course of the novel coronary virus pneumonia to form three targeted traditional Chinese medicine formulas, so that the virus nucleic acid is effectively accelerated to turn negative and the body temperature is reduced in the acute stage of the disease course, the cough and asthma are effectively relieved and relieved, the residual heat is passed through in the severe stage, and the functions of the spleen and the stomach of a patient are restored in the recovery stage by soothing the liver and promoting diuresis.
Drawings
FIG. 1 is a graph of CT images of the lungs of patient 2 in accordance with an embodiment of the present invention;
FIG. 2 is a graph of the lung CT image of patient 13 in accordance with an embodiment of the present invention.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention will be described in further detail with reference to the accompanying drawings and embodiments. It should be understood that the block diagrams and specific examples are set forth only for the purpose of illustrating the invention and are not to be construed as limiting the invention.
Example 1
The invention provides a traditional Chinese medicine composition, which comprises the following components: 3-15 parts of tripterygium wilfordii, 10-50 parts of gypsum, 8-24 parts of raw Chinese yam, 5-15 parts of radix scrophulariae, 4-12 parts of fructus forsythiae, 4-10 parts of periostracum cicada, 4-12 parts of codonopsis pilosula, 3-8 parts of mint, 3-10 parts of burdock and 4-20 parts of raw ochre.
The formula takes the tripterygium wilfordii as a monarch drug, has bitter taste, enters the heart and liver channels, has the effects of dispelling wind and removing dampness, promoting blood circulation and removing obstruction in channels, relieving swelling and pain, and killing parasites and detoxifying, and has good curative effect on viral infection. Gypsum is used as a ministerial drug, is pungent and sweet, is slightly cold, has the effect of supporting qi to clear heat and suppress yang, is cool and capable of dissipating, clears qi and divides heat into evil without damaging yin, and has the external infection with heat directly prevailing on the golden lead. Raw ochre is a ministerial drug, has the effects of suppressing yang and lowering adverse qi, is sweet and cold in cooling blood, and has the effects of clearing heat in blood vessels of five internal organs and removing toxicity, and is matched with monarch drugs to suppress yang and resolve dampness. The raw yam has the effects of nourishing yin, promoting diuresis, invigorating spleen, tonifying lung, reinforcing kidney, benefiting essence, inducing astringency and qi transformation. When used together with gypsum, it can clear heat without damaging yin and nourish yin without affecting body resistance. Radix scrophulariae is sweet, bitter, salty, and slightly cold, and has the effects of nourishing yin, clearing and tonifying, detoxifying and clearing away fire. Forsythia fruit and cicada slough are used together to clear heat and expel pathogenic factors and protect heart yang. Codonopsis pilosula enters spleen and lung and regulates stomach qi. Mint and burdock fruit are used for refreshing the head, eyes and throat.
The traditional Chinese medicine formula is suitable for the acute stage of 2019 novel coronavirus pneumonia diseases, aims at fever patients, takes antivirus as a core, and has the key points of clearing heat and removing toxicity, suppressing yang and regulating immunity. Depending on clinical medication, an average of 3-5 doses of the drug can lower body temperature to the normal range.
Example 2
Composition 1, wherein the pharmaceutical composition comprises: 7.5 parts of tripterygium wilfordii, 15 parts of gypsum, 8 parts of raw Chinese yam, 5 parts of radix scrophulariae, 4 parts of fructus forsythiae, 4 parts of periostracum cicadae, 4 parts of codonopsis pilosula, 3 parts of mint, 3 parts of burdock and 4 parts of raw ochre.
The traditional Chinese medicine composition has the functions of defervescence and virus elimination aiming at the novel coronavirus pneumonia diseases.
Example 3
The invention provides another traditional Chinese medicine composition, which comprises the following components: 2-5 parts of tripterygium wilfordii, 5-10 parts of radix bupleuri, 5-10 parts of pinellia ternate, 3-8 parts of scutellaria baicalensis, 10-20 parts of reed stems, 5-10 parts of exocarpium citri rubrum, 5-10 parts of adenophora stricta, 5-10 parts of radix peucedani, 3-8 parts of platycodon grandiflorum, 5-10 parts of almonds and 3-8 parts of honey-fried licorice roots.
The formula takes the tripterygium wilfordii and the reed stem as monarch drugs, has bitter taste, enters the heart and liver channels, has the effects of dispelling wind and removing dampness, promoting blood circulation and removing obstruction in channels, relieving swelling and pain, and killing parasites and detoxifying, and has good curative effect on viral infection. Radix bupleuri and pinellia ternate are used as ministerial drugs, and exocarpium citri rubrum and platycodon grandiflorum are used as left envoy drugs. The fever with the decline of the heat potential is due to the fever and the lung with the deficiency of the lung-qi.
Cough and asthma are caused by the fact that lung qi is weak and liver qi fails to restrict liver qi, liver qi ascends and reversely restricts lung qi, and cough and asthma are caused by the fact that cough is in a severe stage, heat is relieved, lung qi is deficient and cannot restrict liver qi, and lung qi is reversely restricted and reversely restricted by liver qi and wood. Tripterygium wilfordii is the monarch, and has the core of resisting virus and regulating immunity. The bupleurum-pinellia tuber is used for relieving cough and asthma and expelling excessive heat. Tripterygium wilfordii has the functions of resisting virus and regulating immunity, radix bupleuri regulates liver and wood, pinellia ternate has the functions of reducing phlegm and resolving masses, radix scutellariae clears heat of large intestine to lower lung qi, and phragmites australis to promote water in bladder to descend by heat conduction to clear stagnation of lung. Radix Platycodi has the effects of relieving sore throat, radix Adenophorae and radix Peucedani have the effects of nourishing yin, moistening lung, lowering adverse flow of qi, relieving cough, and semen Armeniacae amarum has the effects of lowering qi, and exocarpium Citri rubrum has the effects of eliminating phlegm, and can be used together for assisting in relieving cough and asthma. Radix Glycyrrhizae Preparata is added for warming to harmonize the recipe.
The formula is suitable for the severe stage of the novel coronavirus pneumonia disease in 2019, and the formula of the tripterygium wilfordii, radix bupleuri and pinellia ternate is used for relieving cough and asthma and clearing residual heat, and 3-5 agents for treating and accelerating virus nucleic acid to turn negative are used.
Example 4
Composition 2: the traditional Chinese medicine composition comprises: 3 parts of tripterygium wilfordii, 9 parts of radix bupleuri, 9 parts of pinellia ternate, 6 parts of scutellaria baicalensis, 15 parts of reed stems, 9 parts of exocarpium citri rubrum, 9 parts of adenophora stricta, 9 parts of radix peucedani, 6 parts of platycodon grandiflorum, 9 parts of almonds and 6 parts of honey-fried licorice roots.
The traditional Chinese medicine composition has the functions of relieving cough and asthma aiming at the novel coronavirus pneumonia diseases.
Example 5
This patent provides another Chinese medicinal composition comprising: 2-5 parts of tripterygium wilfordii, 10-15 parts of snakegourd fruit, 5-10 parts of allium macrostemon, 3-8 parts of poria cocos, 5-10 parts of rhizoma pinellinae praeparata, 3-8 parts of dried orange peel, 3-8 parts of immature bitter orange, 5-10 parts of bamboo shavings, 3-8 parts of rhizoma acori graminei and 3-8 parts of honey-fried licorice root.
The formula adopts tripterygium wilfordii, trichosanthes kirilowii maxim, allium macrostemon and pinellia ternate decoction and gallbladder warming decoction to relieve depression and activate yang, harmonize stomach and promote bile flow. Tripterygium wilfordii is a monarch drug, and has the effects of resisting virus, regulating immunity, lowering lung qi, benefiting diaphragm, relieving chest stuffiness, activating heart yang, eliminating phlegm and regulating stomach, pinellia ternate and caulis bambusae in taeniam, dried orange peel and immature bitter orange are used for regulating qi, activating stagnancy, eliminating phlegm and relieving stuffiness, rhizoma acori graminei is used for eliminating phlegm and inducing resuscitation, and poria cocos is used for tonifying spleen and excreting dampness to serve as a source of phlegm. The liquorice is used for guiding and harmonizing the effects of the drugs in the recipe. The formula is used for relieving depression and activating yang, harmonizing stomach and benefiting gallbladder, and treating severe lung excess.
The traditional Chinese medicine formula is suitable for the recovery period of the novel coronavirus pneumonia disease in 2019, and has the effects of tonifying spleen and promoting diuresis, strengthening fire and eating qi, eliminating pathogenic factors and reducing healthy energy deficiency, mainly strengthening healthy energy, soothing liver and promoting diuresis, and improving symptoms of loose stool and the like, and patients can recover to be normal after taking 3-5 doses of the traditional Chinese medicine formula clinically.
Example 6
Composition 3: 3 parts of tripterygium wilfordii, 12 parts of snakegourd fruit, 9 parts of allium macrostemon, 6 parts of poria cocos, 9 parts of rhizoma pinellinae praeparata, 6 parts of dried orange peel, 6 parts of immature bitter orange, 9 parts of bamboo shavings, 6 parts of rhizoma acori graminei and 6 parts of honey-fried licorice root.
The Chinese medicinal composition has effects of dispelling blood stasis, activating yang, regulating stomach function, promoting bile flow, and recovering digestive function for novel coronavirus pneumonia diseases.
It should be understood that the above-mentioned Chinese medicinal compositions of examples 1-6 all have therapeutic uses of resisting virus and regulating immunity of the body.
During outbreak of the novel coronavirus pneumonia in 2019, the medicine is applied to Jiangxi and Guangxi two places, and 136 clinical patients are shared by 3 months and 3 days in 2020, wherein 70 cases are diagnosed in Xinwei and 66 cases are diagnosed in Guangxi. 28 severe cases diagnosed in Jiangxi account for 40% of the confirmed cases in Jiangxi. The patients with severe diseases include cancer and hypertension, the minimum patient is 4 years old, and the maximum patient is 90 years old. The patients are completely cured by taking different traditional Chinese medicine combinations according to the disease condition and taking traditional Chinese medicine for 4-10 days.
Average negative turning time: the medicine is used for treating the disease by pure traditional Chinese medicines, wherein the first negative conversion rate is 4 days, the first negative conversion rate is 7 days, and the first negative conversion rate is 8.5 days.
Data for some clinical patients are shown in the following table:
Figure BDA0002402680090000071
wherein, aiming at different diseases of patients in emergency, severe or convalescent period, one or the combination of the compositions 1, 2 and 3 is taken by the patients. The composition 1 is taken in a mode of one dose every 1 day, three times in the morning, noon and evening, and 3 days as a treatment course; the composition 2 is taken once a day in the morning and evening, and is taken twice in the morning and evening, and 3 days are a course of treatment; the medicine taking mode of the composition 3 is 1 day for one dose, the medicine is taken once in the morning, and 3 days are a treatment course; .
Wherein after the traditional Chinese medicine is taken, the blood examination comparison summary before and after the taking of the traditional Chinese medicine is as follows:
the two items of NEUT (neutrophil count) and PLT (platelet count) are increased simultaneously, which is a key index for the disease to be cured.
The renal function index SCr (creatinine) is normal.
Liver function indices ALT (alanine), GGT (transglutaminase) were substantially normal.
ALT (alanine) was slightly elevated, consistent with The phenomenon proposed in The Lancet (Jan 29,2020: 17).
The body temperature data before and after the medicine is taken shows that the body temperature of patients is obviously reduced after the medicine is taken for three days, and the body temperature of most patients is reduced to be within a normal range.
The first negative conversion days after the medicine is taken can be known, the detection result of throat swabs of patients is negative within 5 days after most of patients take the medicine, the nucleic acid detection in two times in clinic is negative and is regarded as an index for clearing the virus in vivo, and the second negative conversion days of the virus of the patients are 3 days on average.
The patient No. 11 is a patient stopping, the western medicine moxifloxacin is taken before the patient No. 2 and the patient No. 13 take the traditional Chinese medicine, and the western medicine is changed to take the traditional Chinese medicine to continue treatment after the western medicine does not achieve the treatment effect.
Fig. 1 shows the CT image result of patient 2, the top two panels are the chest CT image result of patient 2 performed 2 days before taking the traditional Chinese medicine, the chest CT shows that both lungs have speckle-shaped fuzzy dense shadow and frosted glass shadow, and both lateral pneumonia and viral pneumonia are not excluded. The two lower panels are lung CT image results 7 days after the traditional Chinese medicine composition is taken, and the two lungs are mostly seen with spot-shaped fuzzy dense images and frosted glass images, so that the density of the focus is reduced compared with that of the front lung, and the obvious absorption of the focus of the lung of a patient treated by the traditional Chinese medicine is proved.
Fig. 1 shows the CT image result of patient 13, and the top two panels show the chest CT image result of patient 2 on the day of taking the traditional Chinese medicine, showing the abnormal density image of both lungs of the patient, considering that the possibility of viral pneumonia is high. The two lower panels show that the lung CT image result 5 days after the traditional Chinese medicine composition is taken shows that the two lungs have abnormal density shadow, and the two lungs are absorbed by the focus of the two lungs compared with the front panel, considering pneumonia and viral pneumonia except for pneumonia. The obvious absorption of the lung focus of the patient treated by the traditional Chinese medicine is proved.
The above-mentioned embodiments only express the embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the present invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.

Claims (10)

1. A traditional Chinese medicine composition applied to viral pneumonia is characterized in that the composition is as follows: 3-15 parts of tripterygium wilfordii, 10-50 parts of gypsum, 8-24 parts of raw Chinese yam, 5-15 parts of radix scrophulariae, 4-12 parts of fructus forsythiae, 4-10 parts of periostracum cicada, 4-12 parts of codonopsis pilosula, 3-8 parts of mint, 3-10 parts of burdock and 4-20 parts of raw ochre.
2. The traditional Chinese medicine composition of claim 1, wherein the composition comprises 7.5 parts by weight of tripterygium wilfordii, 15 parts by weight of gypsum, 8 parts by weight of raw Chinese yam, 5 parts by weight of radix scrophulariae, 4 parts by weight of fructus forsythiae, 4 parts by weight of periostracum cicada, 4 parts by weight of radix codonopsis pilosulae, 3 parts by weight of mint, 3 parts by weight of burdock and 4 parts by weight of raw ochre.
3. A traditional Chinese medicine composition applied to viral pneumonia is characterized in that the composition is as follows: 2-5 parts of tripterygium wilfordii, 5-10 parts of radix bupleuri, 5-10 parts of pinellia ternate, 3-8 parts of scutellaria baicalensis, 10-20 parts of reed stems, 5-10 parts of exocarpium citri rubrum, 5-10 parts of adenophora stricta, 5-10 parts of radix peucedani, 3-8 parts of platycodon grandiflorum, 5-10 parts of almonds and 3-8 parts of honey-fried licorice roots.
4. The Chinese medicinal composition according to claim 3, wherein the composition comprises 3 parts by weight of Tripterygium wilfordii, 9 parts by weight of radix bupleuri, 9 parts by weight of pinellia ternata, 6 parts by weight of Scutellaria baicalensis, 15 parts by weight of Phragmites communis, 9 parts by weight of exocarpium citri rubrum, 9 parts by weight of adenophora stricta, 9 parts by weight of Peucedanum praeruptorum, 6 parts by weight of Platycodon grandiflorum, 9 parts by weight of apricot kernel, and 6 parts by weight of radix Glycyrrhizae Preparata.
5. A traditional Chinese medicine composition applied to viral pneumonia is characterized in that the composition is as follows: 2-5 parts of tripterygium wilfordii, 10-15 parts of snakegourd fruit, 5-10 parts of allium macrostemon, 3-8 parts of poria cocos, 5-10 parts of rhizoma pinellinae praeparata, 3-8 parts of dried orange peel, 3-8 parts of immature bitter orange, 5-10 parts of bamboo shavings, 3-8 parts of rhizoma acori graminei and 3-8 parts of honey-fried licorice root.
6. The traditional Chinese medicine composition according to claim 5, wherein the traditional Chinese medicine composition comprises 3 parts by weight of tripterygium wilfordii, 12 parts by weight of snakegourd fruit, 9 parts by weight of allium macrostemon, 6 parts by weight of poria cocos, 9 parts by weight of rhizoma pinellinae praeparata, 6 parts by weight of dried orange peel, 6 parts by weight of immature bitter orange, 9 parts by weight of bamboo shavings, 6 parts by weight of acorus gramineus and 6 parts by weight of honey-fried licorice root.
7. The composition of any one of claims 1-6, wherein the composition has therapeutic use against viruses and regulating immunity.
8. The Chinese medicinal composition according to claim 1 or 2, wherein the Chinese medicinal composition has the functions of reducing fever and clearing viruses for the novel coronavirus pneumonia diseases.
9. The Chinese medicinal composition according to claim 3 or 4, wherein the Chinese medicinal composition has the use of relieving cough and asthma for the novel coronavirus pneumonia disease.
10. The Chinese medicinal composition according to claim 5 or 6, wherein the Chinese medicinal composition has the functions of removing blood stasis, activating yang, harmonizing stomach, benefiting gallbladder and recovering digestive function against the novel coronavirus pneumonia disease.
CN202010151714.8A 2020-03-06 2020-03-06 Traditional Chinese medicine composition and application thereof Active CN111184805B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010151714.8A CN111184805B (en) 2020-03-06 2020-03-06 Traditional Chinese medicine composition and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010151714.8A CN111184805B (en) 2020-03-06 2020-03-06 Traditional Chinese medicine composition and application thereof

Publications (2)

Publication Number Publication Date
CN111184805A CN111184805A (en) 2020-05-22
CN111184805B true CN111184805B (en) 2021-07-23

Family

ID=70702761

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010151714.8A Active CN111184805B (en) 2020-03-06 2020-03-06 Traditional Chinese medicine composition and application thereof

Country Status (1)

Country Link
CN (1) CN111184805B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111951963B (en) * 2020-07-30 2022-09-02 中翰盛泰生物技术股份有限公司 Application of HBP in prognosis risk early warning of COVID-19 patient

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101011561A (en) * 2006-11-01 2007-08-08 黄达驹 Modern traditional Chinese medicine oral preparation huanglianwendan decoction and production method thereof
CN101229358A (en) * 2008-01-14 2008-07-30 北京中科雍和医药技术有限公司 Chinese traditional medicine compounds for treating pneumonia, emphysema and preparing method thereof
CN101708275A (en) * 2009-11-27 2010-05-19 北京市卫生局临床药学研究所 Chinese medicament for treating flu caused by influenza A(H1N1) and the like
CN103860697A (en) * 2014-03-20 2014-06-18 中国中医科学院广安门医院 Chinese medicine composition for treating exogenous febrile diseases and application thereof
CN106806514A (en) * 2015-11-27 2017-06-09 吴昊 A kind of medicine for treating pneumonia
CN109820936A (en) * 2019-01-17 2019-05-31 昆明市中医医院 A kind of composition and preparation method thereof for treating pneumonia

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101011561A (en) * 2006-11-01 2007-08-08 黄达驹 Modern traditional Chinese medicine oral preparation huanglianwendan decoction and production method thereof
CN101229358A (en) * 2008-01-14 2008-07-30 北京中科雍和医药技术有限公司 Chinese traditional medicine compounds for treating pneumonia, emphysema and preparing method thereof
CN101708275A (en) * 2009-11-27 2010-05-19 北京市卫生局临床药学研究所 Chinese medicament for treating flu caused by influenza A(H1N1) and the like
CN103860697A (en) * 2014-03-20 2014-06-18 中国中医科学院广安门医院 Chinese medicine composition for treating exogenous febrile diseases and application thereof
CN106806514A (en) * 2015-11-27 2017-06-09 吴昊 A kind of medicine for treating pneumonia
CN109820936A (en) * 2019-01-17 2019-05-31 昆明市中医医院 A kind of composition and preparation method thereof for treating pneumonia

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
二陈汤加味治疗小儿迁延性肺炎200例;孙建民等;《中国医药导报》;20110105;第08卷(第01期);第89-90页 *
小儿肺炎辨证论治简介;中医研究院西苑医院儿科;《中国临床医生》;19000101(第12期);第15-16页 *
温胆汤治疗肺炎100例;徐振华;《陕西中医》;19941115(第11期);第515页 *
辛开苦降法治疗小儿喘息性肺炎98例疗效观察;王军仓等;《新中医》;20100605;第42卷(第06期);第26-27页 *

Also Published As

Publication number Publication date
CN111184805A (en) 2020-05-22

Similar Documents

Publication Publication Date Title
CN111298048B (en) Traditional Chinese medicine composition for treating novel coronavirus pneumonia and application thereof
CN111388582B (en) Traditional Chinese medicine composition for treating novel coronavirus pneumonia and application of preparation thereof
CN111773308A (en) Traditional Chinese medicine composition of 'lung-ventilating and toxin-expelling decoction' for preventing and treating new coronary pneumonia and preparation method
WO2021179505A1 (en) Forsythia suspensa and astragalus membranaceus compound preparation, preparation method therefor and application thereof
CN103977314A (en) Medicinal composition for treating respiratory diseases as well as preparation method and application of medicinal composition
CN111388615A (en) Traditional Chinese medicine mixture for preventing and treating pneumonia and preparation method thereof
CN111184805B (en) Traditional Chinese medicine composition and application thereof
CN111643634B (en) Traditional Chinese medicine composition for treating asymptomatic nucleic acid positive novel coronavirus pneumonia
CN106139080A (en) A kind of Chinese medicine preparation of hepatoprotective lung moistening and preparation method thereof
CN112007138B (en) Chinese medicinal mixture prepared from radix bupleuri, rhizoma dioscoreae and rhizoma zingiberis for treating viral pneumonia caused by dampness-toxin blocking lung
CN104623555A (en) Traditional Chinese medicine preparation for treating acute asthmatic bronchitis and preparation method thereof
CN103638488A (en) Traditional Chinese medicine composition for treating pleurisy
CN1569102A (en) Medicine for treating bronchodilatation
CN101138602A (en) Kidney-nourishing gout-treating capsule
CN104116960A (en) Traditional Chinese medicinal preparation for treating hand-foot-and-mouth disease
CN111228366B (en) Traditional Chinese medicine composition for treating viral pneumonia
CN103432457B (en) Chinese medicine preparation for treating viral myocarditis
CN102284023A (en) Chinese medicinal composition for treating asthma
CN105770455A (en) Traditional Chinese medicinal preparation for treating bronchial asthma
CN1320901C (en) Medicine for treating lung carbuncle disease
CN105902943A (en) Medicine composition for treating wind heat cough of children
CN106177561A (en) One treats phthisical Chinese medicine composition
CN105362548A (en) Traditional Chinese medicine for treating allergic asthma
CN1232280C (en) Jiedufeitai medicine for disintoxication and beneficial to lung
CN104274582B (en) A kind of for liver-protecting medicine compositions and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant